Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Current Deferred Revenue: 2017-2024

Historic Current Deferred Revenue for Arcus Biosciences (RCUS) over the last 8 years, with Dec 2024 value amounting to $319.0 million.

  • Arcus Biosciences' Current Deferred Revenue fell 73.35% to $105.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $105.0 million, marking a year-over-year decrease of 73.35%. This contributed to the annual value of $319.0 million for FY2024, which is 19.85% down from last year.
  • Latest data reveals that Arcus Biosciences reported Current Deferred Revenue of $319.0 million as of FY2024, which was down 19.85% from $398.0 million recorded in FY2023.
  • Arcus Biosciences' Current Deferred Revenue's 5-year high stood at $398.0 million during FY2023, with a 5-year trough of $74.6 million in FY2020.
  • In the last 3 years, Arcus Biosciences' Current Deferred Revenue had a median value of $319.0 million in 2024 and averaged $271.3 million.
  • Per our database at Business Quant, Arcus Biosciences' Current Deferred Revenue soared by 965.30% in 2020 and then fell by 19.85% in 2024.
  • Arcus Biosciences' Current Deferred Revenue (Yearly) stood at $74.6 million in 2020, then spiked by 36.78% to $102.0 million in 2021, then decreased by 4.90% to $97.0 million in 2022, then skyrocketed by 310.31% to $398.0 million in 2023, then declined by 19.85% to $319.0 million in 2024.